These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8547753)

  • 21. Breast cancer: clinical decision making.
    Hayes JD; Clark EJ
    Pharmacoeconomics; 1993 Sep; 4(3):226-8. PubMed ID: 10147131
    [No Abstract]   [Full Text] [Related]  

  • 22. [Value of tumor biological prognostic factors in adjuvant therapy of node-negative breast cancer].
    Jänicke F
    Zentralbl Gynakol; 1994; 116(8):449-55. PubMed ID: 7941813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adjuvant treatment of cancer of the breast: cost assessment of the protocol used].
    Selke B; Bercez C; Lenne X; Bonneterre ME; Lebrun T; Bonneterre J
    Bull Cancer; 1998 Nov; 85(11):961-6. PubMed ID: 9951423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is adjuvant chemotherapy omissible in women with T1-2 stage, node-positive, luminal A type breast cancer?
    Kwak HY; Chae BJ; Eom YH; Hong YR; Seo JB; Bae JS; Jung SS; Song BJ
    J Chemother; 2015 Oct; 27(5):290-6. PubMed ID: 25974160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant therapy in breast cancer.
    Robert NJ
    Obstet Gynecol Clin North Am; 1994 Dec; 21(4):693-707. PubMed ID: 7731642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
    Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
    Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effectiveness and other assessments of adjuvant therapies for early breast cancer.
    Hillner BE; Smith TJ
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):129-34. PubMed ID: 8608043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new look at node-negative breast cancer.
    Harbeck N; Thomssen C
    Oncologist; 2011; 16 Suppl 1():51-60. PubMed ID: 21278441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
    Cosler LE; Lyman GH
    Cancer Invest; 2009 Dec; 27(10):953-9. PubMed ID: 19909009
    [No Abstract]   [Full Text] [Related]  

  • 31. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):81-9. PubMed ID: 15607936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
    Oestreicher N; Ramsey SD; McCune JS; Linden HM; Veenstra DL
    Cancer; 2005 Nov; 104(10):2054-62. PubMed ID: 16216002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.
    Niméus-Malmström E; Koliadi A; Ahlin C; Holmqvist M; Holmberg L; Amini RM; Jirström K; Wärnberg F; Blomqvist C; Fernö M; Fjällskog ML
    Int J Cancer; 2010 Aug; 127(4):961-7. PubMed ID: 19957331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
    Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
    Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic tumor markers, lymph node status, and decision about adjuvant chemotherapy for breast cancer.
    Velanovich V
    Am Surg; 1997 Apr; 63(4):330-3. PubMed ID: 9124752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.